The BEAMing Technology: Concordance Between Tissue and Plasma


Jones FS, Edelstein D , Wichner K et al. (2015) Blood based detection of RAS mutations to guide anti‐EGFR therapy in metastatic CRC patients: Concordance of results from circulating tumor DNA and tissue‐based RAS testing. ECC 2015, Abstract 2012. Link: Download poster

Hahn S, Tannapfel A, Friess H (2015) Clinical performance comparison of RAS mutation detection in plasma and tissue samples from stage IV colorectal cancer patients for first‐line anti‐EGFR therapy selection. ECC 2015, Abstract 402


Thress K, Brant R, Carr TH, et al. (2015) EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291. Lung Cancer. 90(3):509-15 Links: Pubmed Free PDF

Jeffers M, Lathia CD, Wilhelm SM, et al.(2013)Detection of tumor-associated mutations in circulating DNA: clinical applications and experiences. AACR 104th Annual Meeting 2013, Abstract SY11-02. Link: Pubmed


Haselmann V, Sucker A, Jones FS, et al. (2015) Concordance of BRAF V600E mutation status in metastatic melanoma patients by comparison of results from circulating tumor DNA and tissue‐based testing. ECC 2015, Abstract  3351.

Ascierto P, Minor D, Ribas A, et al. (2013) Phase II Trial (BREAK-2) of the BRAF inhibitor Dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol. 31(26):3205-11. Links: Pubmed Free PDF

Breast cancer

Higgins M, Jelovac D, Barnathan E, et. al. (2012) Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res. 18(12):3462-9. Links: Pubmed Free PDF